Moonlake Immunotherapeutics (MLTX) Reiterated at Overweight by Cantor Fitzgerald

Tue, 03 Mar 2026 07:00:12 -0500

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Moonlake Immunotherapeutics (NASDAQ: MLTX).

The analyst commented, "The axSpA market is already >$5B, and we estimate on track to be >$10B at peak with the increase in biologic penetration. IL-17 drugs now have majority share in axSpA. Even with conservative share assumptions, axSpA could be a blockbuster indication for SLK, while it appears nothing is priced into the stock at a ~$1.3B market cap, given the focus on HS indication."

For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics

Moonlake Immunotherapeutics (MLTX) PT Raised to $13 at RBC Capital

Mon, 02 Mar 2026 09:11:37 -0500

RBC Capital analyst Brian Abrahams raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $13.00 (from $12.00) while maintaining a Sector Perform rating.

Moonlake Immunotherapeutics (MLTX) PT Raised to $40 at H.C. Wainwright

Mon, 02 Mar 2026 07:00:14 -0500

(Updated - March 2, 2026 7:00 AM EST)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $40.00 (from $32.00) while maintaining a Buy rating.

The analyst commented: "In a recent press release and Investor Day, MoonLake Immunotherapeutics reported top-line results from the S-OLARIS Phase 2 trial of sonelokimab (SLK) in patients with radiographic and non-radiographic axial spondyloarthritis (axSpA). In the Phase 2 S-OLARIS trial in axSpA, SLK displayed clinically meaningful and statistically significant benefit. A total of 81% of patients treated with SLK (n=26, mNRI), achieved an Assessment of Spondyloarthritis International Society 40 (ASAS40) response

Moonlake Immunotherapeutics (MLTX) PT Raised to $40 at H.C. Wainwright

Mon, 02 Mar 2026 07:00:14 -0500

(Updated - March 2, 2026 7:00 AM EST)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $40.00 (from $32.00) while maintaining a Buy rating.

Form 10-K MoonLake Immunotherapeut For: Dec 31

Wed, 25 Feb 2026 06:13:00 -0500

si-local-file:///var/storage/secattach/20260225/26054782.html

Form 10-K MoonLake Immunotherapeut For: Dec 31

Wed, 25 Feb 2026 06:13:00 -0500

si-local-file:///var/storage/secattach/20260225/26054782.html

Moonlake Immunotherapeutics (MLTX) PT Raised to $35 at Oppenheimer

Tue, 24 Feb 2026 08:09:47 -0500

Oppenheimer analyst Andreas Argyrides raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $35.00 (from $30.00) while maintaining a Outperform rating.

Moonlake Immunotherapeutics (MLTX) PT Raised to $19 at Stifel

Mon, 23 Feb 2026 11:04:21 -0500

Stifel analyst Alex Thompson raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $19.00 (from $13.00) while maintaining a Hold rating.

Form 8-K MoonLake Immunotherapeut For: Feb 18

Mon, 23 Feb 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260223/26038752.html

Form 8-K MoonLake Immunotherapeut For: Feb 18

Mon, 23 Feb 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260223/26038752.html

MoonLake reports positive Phase 2 results for axial spondyloarthritis drug

Sun, 22 Feb 2026 11:00:22 -0500

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported that its drug sonelokimab showed clinical benefit in a Phase 2 trial for axial spondyloarthritis, with 81% of patients achieving ASAS40 response by week 12.

The S-OLARIS trial enrolled 26 patients with radiographic and non-radiographic axial spondyloarthritis. More than 80% of patients achieved clinically important improvement as measured by ASDAS-CRP score by week 12. Clinical improvements were confirmed by SPARCC MRI scores in the sacroiliac joint, measuring inflammation and injury inside bone tissue.

PET imaging data showed significant reduction of inflammation and osteoblast activity in sacroiliac joints affected by axial spondyloarthritis. The company said biomarker analyses demonstrated

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

Sun, 22 Feb 2026 11:00:00 -0500

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12
Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRI
axSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

Sun, 22 Feb 2026 11:00:00 -0500

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12
Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRI
axSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease

Moonlake Immunotherapeutics (MLTX) PT Raised to $12 at RBC Capital

Fri, 20 Feb 2026 06:55:31 -0500
RBC Capital analyst Brian Abrahams raised the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $12.00 (from $10.00) while maintaining a Sector Perform rating.

Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Tue, 17 Feb 2026 15:02:00 -0500
si-local-file:///var/storage/secattach/20260217/26011437.html

Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Tue, 17 Feb 2026 15:02:00 -0500
si-local-file:///var/storage/secattach/20260217/26011437.html

ImageneBio names Dr. Ben Porter-Brown as chief medical officer

Tue, 10 Feb 2026 07:00:11 -0500

ImageneBio Inc. (NASDAQ: IMA) appointed Dr. Ben Porter-Brown as chief medical officer, the company announced. Porter-Brown will start the role on February 16, 2026.

Porter-Brown brings over 20 years of experience in autoimmune and inflammatory disease drug development. He most recently served as chief medical officer at MoonLake Immunotherapeutics (NASDAQ: MLTX). Previously, he spent more than five years at Kymab Ltd., now a Sanofi company, where he led development of amlitelimab, an anti-OX40 ligand monoclonal antibody, from early human studies through a Phase 2a trial in atopic dermatitis that led to Sanofi's acquisition of Kymab.

At ImageneBio, Porter-Brown will lead the company's

ImageneBio names Dr. Ben Porter-Brown as chief medical officer

Tue, 10 Feb 2026 07:00:11 -0500

ImageneBio Inc. (NASDAQ: IMA) appointed Dr. Ben Porter-Brown as chief medical officer, the company announced. Porter-Brown will start the role on February 16, 2026.

Porter-Brown brings over 20 years of experience in autoimmune and inflammatory disease drug development. He most recently served as chief medical officer at MoonLake Immunotherapeutics (NASDAQ: MLTX). Previously, he spent more than five years at Kymab Ltd., now a Sanofi company, where he led development of amlitelimab, an anti-OX40 ligand monoclonal antibody, from early human studies through a Phase 2a trial in atopic dermatitis that led to Sanofi's acquisition of Kymab.

At ImageneBio, Porter-Brown will lead the company's

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Tue, 10 Feb 2026 07:00:00 -0500

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership

Will build and lead Imagene’s clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis

Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field,

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Tue, 10 Feb 2026 07:00:00 -0500

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership

Will build and lead Imagene’s clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis

Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field,

BTIG on Moonlake Immunotherapeutics (MLTX): 'An Underappreciated and Large Market Opportunity in Rheumatology'

Mon, 09 Feb 2026 10:01:00 -0500

BTIG analyst Julian Harrison reiterated a Buy rating and $24.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).
The analyst comments "Phase 2 data of sonelokimab (SLK; albumin-binding antiIL-17A/F Nanobody) in axial spondylarthritis (axSpA) are expected to be shared at MLTX’s Investor Day on February 23. With SLK’s hidradenitis suppurativa BLA filing in 2H26 and PDUFA likely in 2H27, we expect focus to turn to MLTX’s major rheumatology catalysts in the remainder of 2026. We see favorable risk/reward through the Phase 2 axSpA data considering the little credit and attention the opportunity has historically been given, despite the significant unmet need and

H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Tue, 03 Feb 2026 06:45:00 -0500

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $32.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).
The analyst commented: "Yesterday, MoonLake reported that the FDA had granted Fast Track designation for sonelokimab (SLK) in moderate‑to‑severe palmoplantar pustulosis (PPP). MoonLake had originally submitted a request for Fast Track designation on December 1, 2025. As a reminder, Fast Track designation is an FDA program designed to facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Granting Fast Track designation is generally based on whether a drug has the potential to improve survival,

MoonLake receives FDA fast track designation for sonelokimab PPP treatment

Mon, 02 Feb 2026 08:00:13 -0500

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced that the FDA has granted Fast Track designation for sonelokimab for treating moderate-to-severe palmoplantar pustulosis (PPP). The company submitted the Fast Track request on December 1, 2025.

Fast Track designation is designed to facilitate development and expedite review of drugs treating serious conditions with unmet medical need. The designation reflects the absence of approved treatments for PPP, a chronic inflammatory condition affecting the palms and soles of feet.

The FDA decision was supported by positive results from the Phase 2 LEDA trial, where patients treated with sonelokimab achieved a mean 64% reduction in disease severity scores at

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Mon, 02 Feb 2026 08:00:00 -0500

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trial
The upcoming Phase 3 program will therefore be expected to benefit from earlier and more frequent interactions with the FDA under the Fast Track program, potentially enabling a more efficient development pathway
This regulatory decision follows the recent clear guidance from the FDA, in which the Company confirmed its clinical evidence strategy for the planned submission of a Biologic License Application (BLA) in H2

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Mon, 02 Feb 2026 08:00:00 -0500

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trial
The upcoming Phase 3 program will therefore be expected to benefit from earlier and more frequent interactions with the FDA under the Fast Track program, potentially enabling a more efficient development pathway
This regulatory decision follows the recent clear guidance from the FDA, in which the Company confirmed its clinical evidence strategy for the planned submission of a Biologic License Application (BLA) in H2

StreetInsider.com News Articles

Moonlake Immunotherapeutics (MLTX) Reiterated at Overweight by Cantor Fitzgerald

Moonlake Immunotherapeutics (MLTX) PT Raised to $13 at RBC Capital

Moonlake Immunotherapeutics (MLTX) PT Raised to $40 at H.C. Wainwright

Moonlake Immunotherapeutics (MLTX) PT Raised to $40 at H.C. Wainwright

Form 10-K MoonLake Immunotherapeut For: Dec 31

Form 10-K MoonLake Immunotherapeut For: Dec 31

Moonlake Immunotherapeutics (MLTX) PT Raised to $35 at Oppenheimer

Moonlake Immunotherapeutics (MLTX) PT Raised to $19 at Stifel

Form 8-K MoonLake Immunotherapeut For: Feb 18

Form 8-K MoonLake Immunotherapeut For: Feb 18

MoonLake reports positive Phase 2 results for axial spondyloarthritis drug

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

Moonlake Immunotherapeutics (MLTX) PT Raised to $12 at RBC Capital

Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP

ImageneBio names Dr. Ben Porter-Brown as chief medical officer

ImageneBio names Dr. Ben Porter-Brown as chief medical officer

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

BTIG on Moonlake Immunotherapeutics (MLTX): 'An Underappreciated and Large Market Opportunity in Rheumatology'

H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

MoonLake receives FDA fast track designation for sonelokimab PPP treatment

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day